FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> CDC | Zostavax | Merck

CDC backs wide use of Merck's Zostavax

Tools

TODAY'S SPOTLIGHT... CDC backs wide use of Merck's Zostavax
The Centers for Disease Control and Prevention is giving a boost to Merck's Zostavax vaccine. The public health agency is recommending that all adults 60 years and older should get the herpes zoster shot to prevent shingles, a painful and sometimes long-lasting disease. Complications of shingles, such a pneumonia and blindness, are more common among older folks. The CDC's advice comes after a long peer-review process, and its official stamp could prompt more doctors to give the vaccine--and, importantly, more private insurance companies to cover it. Release | Report

More stories about Merck   CDC   Zostavax  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.